(NBIX) Neurocrine Biosciences, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NBIX) Neurocrine Biosciences, Inc. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This Neurocrine Biosciences, Inc. Ansoff Matrix Analysis helps you assess the company’s growth options across market penetration, market development, product development, and diversification in a clear, structured framework; the page already includes a real preview/sample so you can evaluate style and substance before buying. Purchase the full version to receive the complete, ready-to-use analysis for strategy, investment, or planning.
Market Penetration
INGREZZA in tardive dyskinesia
INGREZZA is Neurocrine Biosciences, Inc.'s main commercial asset for tardive dyskinesia, so market penetration means getting more use from the same specialist base. In a U.S. pool of about 600,000 people with tardive dyskinesia, the real lever is more starts, better persistence, and stronger refills. That supports higher script volume without needing a new indication.
ONGENTYS in Parkinson’s add-on therapy
ONGENTYS is an add-on to levodopa/DOPA decarboxylase inhibitors, so market penetration depends on neurologists moving it into the current Parkinson’s pathway. Neurocrine Biosciences, Inc. is using it to deepen its movement-disorder franchise rather than open a new market. That makes adoption, not category creation, the main growth lever.
ORILISSA in endometriosis pain
ORILISSA is a same-market share play in moderate to severe endometriosis pain, aimed at deepening use within the same women’s health specialist base. Endometriosis affects about 1 in 10 women of reproductive age, giving Neurocrine Biosciences, Inc. a large, established patient pool to defend and grow from an approved brand already on market since 2018.
ORIAHNN in uterine fibroid bleeding
ORIAHNN is a direct existing-product, existing-market push for Neurocrine Biosciences, Inc.: it targets pre-menopausal women with heavy menstrual bleeding from uterine fibroids, a condition that affects up to 70% of women by age 50. In this market, penetration means winning more prescriptions from clinicians who already treat fibroid bleeding, not creating a new category.
That matters because 1 in 3 women with fibroids report heavy bleeding, and ORIAHNN offers an oral, non-surgical option that can fit earlier in treatment paths. The commercial goal is simple: raise awareness, improve trial rates, and convert gynecology visits into repeat use.
- Existing product
- Existing market
- Clinician adoption drive
- Oral, non-surgical option
AbbVie women’s health commercialization
Neurocrine’s women’s health penetration is tied to its collaboration with AbbVie Inc., which commercializes 2 key assets, ORILISSA and ORIAHNN. This expands reach in a current market where ORILISSA launched in 2018 and ORIAHNN in 2020, helping Neurocrine deepen share without building a full standalone sales force.
AbbVie’s larger women’s health sales network gives these products wider physician access and payer coverage, which is the clearest market-penetration lever in the Ansoff matrix. The partnership is practical, asset-light, and aimed at growing volume in an existing category.
- 2 marketed women’s health assets
- ORILISSA: 2018 launch
- ORIAHNN: 2020 launch
- Uses AbbVie’s commercial scale
Neurocrine’s Growth Play: More Volume From Existing Brands
Neurocrine Biosciences, Inc.’s market penetration play is about pushing more volume from existing brands in current specialist channels: INGREZZA in tardive dyskinesia, ONGENTYS in Parkinson’s disease, and ORILISSA/ORIAHNN in women’s health. The key levers are higher starts, better refill rates, and broader physician adoption in large diagnosed pools.
| Asset | Market | Penetration lever |
|---|---|---|
| INGREZZA | ~600,000 TD patients | Starts and persistence |
| ORILISSA | Endometriosis | Share gain |
| ORIAHNN | Fibroid bleeding | Physician adoption |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix view of Neurocrine Biosciences, Inc.’s growth strategy across existing and new products and markets
Editable Excel File
Provides a clear Neurocrine Biosciences Ansoff Matrix snapshot to quickly pinpoint growth options and reduce strategy uncertainty.
Reference Sources
Cites primary, regulatory, and industry sources to fast-verify Neurocrine Biosciences growth paths in Ansoff Matrix analyses.
Market Development
INGREZZA across broader specialty channels
INGREZZA can expand from early adopters into broader neurology and psychiatry referral channels, so Neurocrine Biosciences, Inc. widens the buyer base without changing the drug. In 2024, INGREZZA delivered about $1.9 billion in net product sales, showing strong demand to scale into more prescribing settings. That makes this a classic market development move: same brand, more clinics, more patients, more scripts.
ONGENTYS in movement-disorder centers
ONGENTYS is a levodopa add-on for Parkinson’s disease, so market development means pushing the same product into more movement-disorder centers and specialist clinics. Parkinson’s affects nearly 1 million people in the U.S., and ONGENTYS is dosed once daily at 50 mg or 25 mg with levodopa, which fits routine specialist care. Neurocrine expands reach without changing the indication, lifting access in centers that manage OFF episodes.
ORILISSA through women’s health specialists
ORILISSA can grow by reaching more gynecology and women’s health prescribers, since this is a new channel expansion, not a new product launch. Neurocrine Biosciences, Inc. is still selling the same FDA-approved therapy for endometriosis pain, so wider prescriber access can lift use without new development risk.
ORIAHNN in broader fibroid care pathways
ORIAHNN treats heavy menstrual bleeding linked to uterine fibroids in premenopausal women, so market development means moving it beyond narrow specialist use into broader fibroid care pathways. Uterine fibroids affect up to 77% of women by age 50, and only a share are diagnosed, so the same product can reach more women through OB/GYN, primary care, and anemia workups.
- Same therapy, wider care access
- Targets premenopausal fibroid pathways
Partner-led reach beyond direct promotion
Neurocrine Biosciences, Inc. can widen reach in specialist women’s health by using AbbVie’s sales force and payer access instead of relying only on direct promotion. That matters for niche brands like Orilissa and Oriahnn, where specialist prescribers and access hurdles shape uptake. Partner-led selling can lift market development faster and at lower fixed cost.
- AbbVie broadens field coverage.
- Specialist access improves launch speed.
- Direct spend stays focused.
Neurocrine Grows by Expanding Approved Brands Into New Care Settings
Market development for Neurocrine Biosciences, Inc. means using the same approved brands in more care settings, not changing the drugs. INGREZZA reached about $1.9 billion in 2024 net product sales, while ORILISSA, ORIAHNN, and ONGENTYS can gain by expanding into more neurology, OB/GYN, and movement-disorder channels.
| Brand | Market development lever | Latest cited data |
|---|---|---|
| INGREZZA | Broader neuropsychiatry access | 2024 sales: about $1.9B |
Preview Before You Purchase
Neurocrine Biosciences, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, covering Neurocrine Biosciences' product-market strategies and recommended growth pathways.
Product Development
NBI-921352 epilepsy program
NBI-921352 is a new product in clinical development for 2 groups: pediatric patients and adults with focal epilepsy, so it fits Ansoff Matrix market development inside Neurocrine Biosciences, Inc.’s core neuroscience area. It supports the company’s strategy of turning pipeline assets into approved therapies, while targeting an existing epilepsy market with a differentiated next wave asset. Neurocrine Biosciences, Inc. reported $1.9 billion in 2024 revenue, showing the scale behind this pipeline push.
NBI-827104 rare pediatric epilepsy and essential tremor
NBI-827104 is a direct product-development move: Neurocrine Biosciences, Inc. is moving it from discovery into clinical testing for rare pediatric epilepsy and essential tremor. That broadens the pipeline beyond its core neuroscience base, where 2025 net product sales were still led by INGREZZA at more than $2 billion. Rare epilepsy also matters because severe childhood epilepsy affects about 1 in 200 children.
NBI-1065845 major depressive disorder
NBI-1065845 is Neurocrine Biosciences, Inc.'s psychiatry candidate for major depressive disorder, so this is product development: a new therapy aimed at an established market. Neurocrine Biosciences, Inc. reported $2.4 billion in 2025 revenue, and adding NBI-1065845 broadens its CNS pipeline beyond approved products like INGREZZA. If successful, it could open a new growth lane in depression, a large and still underserved market.
NBI-1065846 anhedonia in MDD
NBI-1065846 is a symptom-targeted MDD asset aimed at anhedonia, the loss of pleasure that drives poor function and often persists even when mood lifts. That makes it a differentiated new-product bet in Neurocrine Biosciences, Inc.’s depression franchise, with MDD affecting about 280 million people worldwide and anhedonia reported in roughly 40% to 70% of MDD cases.
In Ansoff terms, this is product development: a new therapy for an existing psychiatric market, but narrowed to a defined symptom segment. The strategy can improve clinical fit and pricing power if it proves better than broad antidepressants, where only about one-third of patients reach remission after first treatment.
- Targets a high-burden MDD symptom
- Refines the pipeline to anhedonia
- Fits product development, not market expansion
- Uses a differentiated, niche depression concept
NBI-118568 schizophrenia program
NBI-118568 is Neurocrine Biosciences, Inc.’s schizophrenia candidate, so this is a clear product-development move that pushes its CNS pipeline beyond current commercial brands. Schizophrenia affects about 24 million people worldwide, and the U.S. schizophrenia drugs market is still a multibillion-dollar space, so even a small share can matter.
- Expands psychiatric reach
- Targets a large CNS market
- Adds pipeline depth beyond brands
Neurocrine’s Pipeline Push Fuels the Next Phase of CNS Growth
Neurocrine Biosciences, Inc.’s product development strategy centers on new CNS and psychiatry assets, including NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. These programs extend its pipeline into epilepsy, depression, anhedonia, and schizophrenia, while building on 2025 revenue of $2.4 billion and INGREZZA sales above $2 billion. This is classic product development: new products for existing disease markets.
| Asset | Ansoff move | 2025 data point |
|---|---|---|
| NBI-1065845 | Product development | MDD target |
| NBI-118568 | Product development | Schizophrenia target |
| Neurocrine Biosciences, Inc. | Pipeline-backed growth | $2.4B revenue |
Diversification
8 strategic partners network
Neurocrine Biosciences has 8 strategic partners, including Heptares, Takeda, Idorsia, Xenon, Voyager, BIAL, Mitsubishi Tanabe, and AbbVie. This licensing and collaboration web spreads R&D risk across multiple external innovation sources and business models. It also reduces reliance on a single program, which can protect pipeline value if one partner or asset underperforms.
Heptares and Takeda collaborations
Heptares Therapeutics and Takeda Pharmaceutical give Neurocrine Biosciences two external science channels, so growth is not tied only to its internal pipeline. That is diversification through partnered innovation, with access to outside assets, targets, and development risk sharing. It also broadens Neurocrine’s shot at new CNS programs without building every asset in-house.
Idorsia and Xenon partnerships
Idorsia and Xenon give Neurocrine Biosciences, Inc. more outside neuroscience links, which adds option value in new programs and mechanisms. That matters because one approved brand, INGREZZA, drove about $2.5 billion in 2024 sales, so more shots on goal can lower single-product risk. It also spreads discovery exposure beyond one path and one deal.
Voyager gene-therapy linkage
Voyager Therapeutics gives Neurocrine Biosciences a gene-therapy route outside its core small-molecule play, so the tie-up is true diversification, not just brand extension. It widens R&D exposure to CNS delivery and long-duration treatment models, which can change the pipeline mix and risk profile.
- Moves beyond internal brand expansion
- Adds gene-therapy science and delivery know-how
- Broadens product and partner exposure
BIAL and Mitsubishi Tanabe regional reach
BIAL Portela & Ca and Mitsubishi Tanabe Pharma give Neurocrine Biosciences, Inc. a 2-partner footprint across Europe and Japan, so diversification is not just by product but by geography too. That wider reach can lower single-market risk and support future cross-border development and commercialization.
With 2 established partners, Neurocrine Biosciences, Inc. can share development cost and regulatory load across markets, which matters when one program faces delays or a weaker launch in one region. The setup also spreads commercial risk across 2 separate demand bases.
- 2 partners, wider geography
- Europe and Japan access
- Shared product and launch risk
- Supports cross-border expansion
Neurocrine Spreads Risk with 8 Strategic Partners
Neurocrine Biosciences uses diversification through 8 strategic partners, not just internal R&D. That spreads discovery risk across CNS, gene therapy, and regional deals.
| Item | Data |
|---|---|
| Partners | 8 |
| INGREZZA sales | $2.5B |
| Geographies | Europe, Japan |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.